Skip to content
DataLookout
Menu

NCT04242095

Collection of Research Data and Samples From Patients Treated With Immunotherapy to Study Its Side Effects

StatusRecruiting
PhaseNot specified
Primary completion (estimated)

At risk: Primary completion moved 12 months later.

Track this trial

Free. We email you which fields changed when ClinicalTrials.gov updates this record.

Record History

The 50 most recent of 55 versions: 50 with changes below. See every version on ClinicalTrials.gov ↗

  1. Notable Primary and study completion pushed from Oct 1, 2026 to Oct 1, 2027
    • Study sites: 629 to 630
  2. Minor Trial sites expanded: 625 → 629 locations
  3. Notable Enrollment increased: 240 → 2240 participants Show 4 more changesShow less
    • Eligibility criteria expanded, about 168 words
    • Site details revised at 46 of 625 sites
    • Study description shortened, about 2 words
    • Study title expanded, about 3 words
  4. Minor Site contacts updated at 5 of 625 sitesv52
  5. Minor Study sites revised (625)v51
Show 45 earlier versionsHide 45 earlier versions
  1. Minor Study sites: 626 to 625v50
  2. Minor Study sites revised (626)v49
  3. Minor Study sites revised (626)v48
  4. Minor Study sites: 625 to 626v47
  5. Minor Site details revised at 1 of 625 sitesv46
  6. Minor Site details revised at 3 of 625 sitesv45
  7. Minor Study sites: 623 to 625v44
  8. Minor Study sites: 622 to 623v43
  9. Minor Study sites revised (622)v42
  10. Minor Study sites: 621 to 622v41
  11. Minor Study sites: 620 to 621v40
  12. Minor Study sites: 610 to 620v39
  13. Minor Study sites: 604 to 610v38
  14. Notable Primary and study completion dates: Oct 1, 2025 to Oct 1, 2026
    • Start date: Jan 31, 2020 to Mar 12, 2020
    • Site details revised at 485 of 604 sites
    v37
  15. Minor Study sites: 601 to 604v36
  16. Minor Study sites: 595 to 601v35
  17. Minor Study sites: 574 to 595v34
  18. Minor Study sites: 573 to 574v33
  19. Minor Study sites: 570 to 573v32
  20. Minor Study sites: 566 to 570v31
  21. Minor Study sites: 563 to 566v30
  22. Minor Study sites: 546 to 563v29
  23. Minor Study sites: 519 to 546v28
  24. Notable Primary and study completion dates pushed to Oct 1, 2025v27
  25. Minor Study sites revised (519)v26
  26. Minor Site details revised at 6 of 519 sitesv25
  27. Minor Study sites: 517 to 519v24
  28. Minor Study sites: 514 to 517v23
  29. Minor Study sites: 513 to 514v22
  30. Minor Study sites: 506 to 513v21
  31. Minor Study sites: 505 to 506v20
  32. Minor Study sites: 504 to 505v19
  33. Minor Study sites: 502 to 504v18
  34. Minor Study sites revised (502)v17
  35. Minor Study sites: 492 to 502v16
  36. Minor Study sites revised (492)v15
  37. Minor Study sites: 491 to 492v14
  38. Minor Study sites: 488 to 491v13
  39. Minor Study sites: 484 to 488v12
  40. Minor Study sites: 483 to 484v11
  41. Minor Study sites: 461 to 483v10
  42. Minor Study sites: 449 to 461v9
  43. Minor Study sites: 433 to 449v8
  44. Minor Study sites: 381 to 433v7
  45. Minor Study sites: 366 to 381v6
  • Notable: the plan changed
  • Minor: routine updates

Endpoints

Primary

Establishment of a national biorepository including biospecimen and clinical data collections for future use
Timeframe: Up to 1 year

Arms and interventions

Observational (biospecimen collection, medical record review)

Patients undergo collection of tissue and blood samples (and optional stool samples from patients experiencing colitis) at the time of registration (within 72 hours of confirmation of one or more severe irAEs) and at 1 month after registration. Patients' medical records are also reviewed for up to 1 year.

Procedures: Biospecimen Collection

Other: Medical Chart Review

Sites

630 sites in 1 country